

# Endometrial Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/E67D54F20378EN.html>

Date: October 2022

Pages: 532

Price: US\$ 2,500.00 (Single User License)

ID: E67D54F20378EN

## Abstracts

Endometrial Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Endometrial Cancer - Drugs In Development, 2022, provides an overview of the Endometrial Cancer (Oncology) pipeline landscape.

Endometrial cancer is cancer that starts in the endometrium, the lining of the uterus (womb). Endometrial cancer is the most common type of uterine cancer. Although the exact cause of endometrial cancer is unknown, increased levels of estrogen appear to play a role. Estrogen helps stimulate the buildup of the lining of the uterus. Symptoms of endometrial cancer include abnormal bleeding from the vagina, including bleeding between periods or spotting/bleeding after menopause, extremely long, heavy or frequent episodes of vaginal bleeding after age 40, lower abdominal pain or pelvic cramping and thin white or clear vaginal discharge after menopause.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Endometrial Cancer - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Endometrial Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the

descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Endometrial Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Endometrial Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 11, 147, 100, 8, 29 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 4, 7 and 3 molecules, respectively.

Endometrial Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Endometrial Cancer (Oncology).

The pipeline guide reviews pipeline therapeutics for Endometrial Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration

details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Endometrial Cancer (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Endometrial Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Endometrial Cancer (Oncology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Endometrial Cancer (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Endometrial Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Global Markets Direct Report Coverage

Endometrial Cancer - Overview

Endometrial Cancer - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Endometrial Cancer - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Endometrial Cancer - Companies Involved in Therapeutics Development

Endometrial Cancer - Drug Profiles

Endometrial Cancer - Dormant Projects

Endometrial Cancer - Discontinued Products

Endometrial Cancer - Product Development Milestones

Featured News & Press Releases

Sep 29, 2022: Imvax presents new data on personalized whole-tumor derived immunotherapeutic platform at 2022 International Cancer Immunotherapy Conference

Sep 13, 2022: Eisai presents new data on lenvatinib from its oncology portfolio and pipeline at ESMO Congress 2022

Aug 17, 2022: Mersana begins dosing in Phase I solid tumour therapy trial

Aug 03, 2022: ProfoundBio receives FDA 'Study May Proceed' Letter for PRO1184, a Folate Receptor Alpha-Directed ADC with a Topoisomerase 1 inhibitor payload, and welcomes Naomi Hunder, M.D., as Chief Medical Officer

Jul 14, 2022: Theratechnologies provides update on the dose escalation portion of Fast Track designated TH1902 first-in-human study in advanced resistant malignancies

Jul 12, 2022: Leap Therapeutics announces initiation of new DKN-01 clinical trials in gastric cancer, colorectal cancer and endometrial cancer

Jun 27, 2022: Harbour BioMed announces IND clearance for B7H4x4-1BB bispecific antibody by the U.S. Food and Drug Administration

Jun 03, 2022: Made-in-Singapore cancer drug ETC-159 advances in clinical trials

May 26, 2022: Karyopharm to present new Selinexor data at the 2022 American Society of Clinical Oncology Annual Meeting

May 11, 2022: Amber Specialty Pharmacy added to Eisai's LENVIMA Network

May 05, 2022: Context Therapeutics announces poster presentation at the upcoming 2022 ASCO Annual Meeting

Apr 28, 2022: Clovis Oncology highlights Rubraca data to be presented at 2022 ASCO Annual Meeting

Apr 27, 2022: Karyopharm announces selinexor data to be presented at the 2022 American Society of Clinical Oncology Annual Meeting

Apr 08, 2022: Sutro Biopharma presents nonclinical data for antibody-drug conjugate STRO-002 at the AACR Annual Meeting 2022

Apr 05, 2022: Nurix Therapeutics doses first patient in phase 1 clinical trial of DeTIL-0255, a drug-enhanced cell therapy for the treatment of patients with solid tumors

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Endometrial Cancer, 2022  
Number of Products under Development by Companies, 2022  
Number of Products under Development by Universities/Institutes, 2022  
Products under Development by Companies, 2022  
Products under Development by Universities/Institutes, 2022  
Number of Products by Stage and Target, 2022  
Number of Products by Stage and Mechanism of Action, 2022  
Number of Products by Stage and Route of Administration, 2022  
Number of Products by Stage and Molecule Type, 2022  
Endometrial Cancer - Dormant Projects, 2022  
Endometrial Cancer - Discontinued Products, 2022  
Endometrial Cancer - Discontinued Products, 2022 (Contd..1)

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Endometrial Cancer, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022



## I would like to order

Product name: Endometrial Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/E67D54F20378EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E67D54F20378EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

